FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models

The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports Jg. 14; H. 1; S. 787 - 15
Hauptverfasser: Galpin, Kristianne J. C., Rodriguez, Galaxia M., Maranda, Vincent, Cook, David P., Macdonald, Elizabeth, Murshed, Humaira, Zhao, Shan, McCloskey, Curtis W., Chruscinski, Andrzej, Levy, Gary A., Ardolino, Michele, Vanderhyden, Barbara C.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Nature Publishing Group UK 08.01.2024
Nature Publishing Group
Nature Portfolio
Schlagworte:
631/67/1059/2325
631/67/580
Animal models
Animals
Antigen-Presenting Cells
BRCA2 protein
Breast cancer
Carcinoma, Ovarian Epithelial
CD226 antigen
CD25 antigen
CD40 antigen
CD86 antigen
Cell activation
Dendritic cells
Down-regulation
Female
Fgl2 protein
Fibrinogen
Glioblastoma
Humanities and Social Sciences
Humans
Immunoregulation
Immunotherapy
Liver cancer
Lymphocytes
Lymphocytes T
Macrophages
Male
Melanoma
Metastases
Mice
Monocytes
multidisciplinary
Natural killer cells
Oncolysis
Ovarian cancer
Ovarian Neoplasms - therapy
Prostate cancer
Prostatic Neoplasms
Science
Science (multidisciplinary)
Tumor Microenvironment
Tumors
ISSN:2045-2322, 2045-2322
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Abstract The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8- p53 −/− Brca2 −/− ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.
AbstractList The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8- p53 −/− Brca2 −/− ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.
The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8-p53−/−Brca2−/− ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.
The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8-p53-/-Brca2-/- ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8-p53-/-Brca2-/- ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.
The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8-p53−/−Brca2−/− ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.
The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8-p53 Brca2 ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.
Abstract The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), a Treg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well as T cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells in the TME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) in the TME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8-p53 −/− Brca2 −/− ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.
ArticleNumber 787
Author Rodriguez, Galaxia M.
McCloskey, Curtis W.
Ardolino, Michele
Maranda, Vincent
Cook, David P.
Chruscinski, Andrzej
Galpin, Kristianne J. C.
Zhao, Shan
Vanderhyden, Barbara C.
Levy, Gary A.
Macdonald, Elizabeth
Murshed, Humaira
Author_xml – sequence: 1
  givenname: Kristianne J. C.
  surname: Galpin
  fullname: Galpin, Kristianne J. C.
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 2
  givenname: Galaxia M.
  surname: Rodriguez
  fullname: Rodriguez, Galaxia M.
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 3
  givenname: Vincent
  surname: Maranda
  fullname: Maranda, Vincent
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 4
  givenname: David P.
  surname: Cook
  fullname: Cook, David P.
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 5
  givenname: Elizabeth
  surname: Macdonald
  fullname: Macdonald, Elizabeth
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 6
  givenname: Humaira
  surname: Murshed
  fullname: Murshed, Humaira
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 7
  givenname: Shan
  surname: Zhao
  fullname: Zhao, Shan
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 8
  givenname: Curtis W.
  surname: McCloskey
  fullname: McCloskey, Curtis W.
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
– sequence: 9
  givenname: Andrzej
  surname: Chruscinski
  fullname: Chruscinski, Andrzej
  organization: Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, University of Toronto
– sequence: 10
  givenname: Gary A.
  surname: Levy
  fullname: Levy, Gary A.
  organization: Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, University of Toronto
– sequence: 11
  givenname: Michele
  surname: Ardolino
  fullname: Ardolino, Michele
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Biochemistry, Microbiology and Immunology, University of Ottawa
– sequence: 12
  givenname: Barbara C.
  surname: Vanderhyden
  fullname: Vanderhyden, Barbara C.
  email: bvanderhyden@ohri.ca
  organization: Cancer Therapeutics Program, Ottawa Hospital Research Institute, Department of Cellular and Molecular Medicine, University of Ottawa
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38191799$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1P3DAUjCqqQil_oIfKUi-9hPojTpxTVaFCkVbi0p6tF-dl8Sqxt7aziH9fZxda4IB9sOU3Mx69ee-LI-cdFsVHRs8ZFeprrJhsVUl5VUrGWVOyN8UJp5UsueD86Mn9uDiLcUPzkrytWPuuOBaKtaxp25Pi7vJqxck2-MknjCTNk58DWQd_l24JuJ5ASuhmWIrWDXZMAZL1jviBgEl2lys9sdM0OyQGx3GBkQlHcH6CvYLfQbDgiAFnMJDJ9zjGD8XbAcaIZw_nafH78sevi5_l6ubq-uL7qjSyYqlEURuloBdNy5HVlewHZNhhxyhtVNWpFgTUDIFVTSdBCdNXlLGh6yWIGoQ4La4Pur2Hjd4GO0G41x6s3j_4sNYQkjUj6rajiH2naC1M_qgBkLRTTc3ACKn4kLW-HbS2czdhb9DlZozPRJ9XnL3Va7_TjDZNxdvFzZcHheD_zBiTnmxcugYO_Rw1bxmXy6YZ-vkFdJOTcblXC4rVtcrRZtSnp5b-eXkMOAPUAWCCjzHgoI1N-wSzQztma3oZJ30YJ53HSe_HSbNM5S-oj-qvksSBFDPYrTH8t_0K6y8g1d4f
CitedBy_id crossref_primary_10_3389_fonc_2024_1447113
crossref_primary_10_1016_j_gene_2025_149284
crossref_primary_10_1038_s41467_025_58999_6
crossref_primary_10_1172_jci_insight_182563
crossref_primary_10_1186_s12943_025_02411_w
crossref_primary_10_1080_2162402X_2024_2423983
crossref_primary_10_1242_dmm_052177
crossref_primary_10_1002_adma_202413392
Cites_doi 10.1158/2767-9764.CRC-22-0017
10.1002/hep.22684
10.1111/ajt.13696
10.1093/jnci/djv137
10.1371/journal.pone.0206223
10.1016/j.celrep.2015.03.006
10.1182/blood-2009-08-238469
10.1016/j.immuni.2005.01.016
10.3389/fonc.2014.00053
10.7150/ijbs.19398
10.1002/cam4.1528
10.1016/j.cell.2018.09.006
10.1016/j.immuni.2014.02.012
10.1158/2326-6066.CIR-14-0015
10.1046/j.1365-2567.2002.01412.x
10.1073/pnas.1314505111
10.4049/jimmunol.1900059
10.1007/s12032-014-0181-7
10.1126/sciadv.abi7640
10.1126/sciadv.aay9269
10.1111/j.1478-3231.2012.02865.x
10.1371/journal.pone.0072309
10.1016/S0002-9440(10)64992-9
10.1186/s12879-018-3473-2
10.1007/s12026-017-8965-4
10.1093/carcin/21.4.585
10.1371/journal.pone.0019104
10.1002/eji.200838338
10.1080/08820139.2020.1813757
10.4049/jimmunol.180.1.249
10.1016/j.ebiom.2018.04.020
10.1136/gutjnl-2012-302239
10.1016/S1535-6108(03)00241-1
10.1128/JVI.00851-08
10.3389/fimmu.2018.00441
10.1158/0008-5472.CAN-20-0521
10.3390/cancers10080244
10.3389/fimmu.2019.00168
10.3389/fimmu.2021.724276
10.1038/ni.1674
10.1016/j.immuni.2019.12.006
10.1016/j.thromres.2014.11.023
10.4049/jimmunol.170.8.4036
10.1016/j.cell.2017.08.027
10.3389/fimmu.2018.00087
10.1016/j.immuni.2016.05.001
10.1016/j.immuni.2021.08.020
10.3390/cancers10080242
10.1038/s41467-020-18794-x
10.4049/jimmunol.174.11.7403
10.1038/s41598-017-13149-x
10.3109/03009742.2010.536163
10.1093/jnci/djy107
10.1186/ar2336
10.1002/eji.1830050208
10.1046/j.1432-1033.2003.03595.x
10.1038/s41467-018-08271-x
10.1371/journal.pntd.0003755
10.1038/s41588-020-0636-z
10.3748/wjg.v23.i15.2673
10.1038/s41591-018-0096-5
10.1038/ni1582
10.1007/978-1-4615-5331-1_79
10.4049/jimmunol.161.1.138
10.1038/s41591-021-01323-8
10.1111/imm.12897
10.3748/wjg.14.5980
10.1038/s41422-020-0355-0
10.1128/iai.41.3.992-997.1983
10.1172/JCI18114
10.1126/sciadv.aax0629
10.1002/jgm.3023
10.1097/01.cji.0000436722.46675.4a
10.1371/journal.pone.0155189
10.1093/intimm/dxw020
10.1016/j.jhep.2010.04.020
10.1186/s13046-019-1326-5
10.1016/j.jim.2004.08.008
10.1158/0008-5472.CAN-16-1272
10.1016/S0140-6736(21)01206-X
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88A
88E
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M1P
M2P
M7P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s41598-024-51217-1
DatabaseName SpringerOpen Free (Free internet resource, activated by CARLI)
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
ProQuest Health & Medical Collection
Medical Database
Science Database
Biological Science Database
Proquest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic (retired)
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
Publicly Available Content Database
MEDLINE - Academic

MEDLINE
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: PIMPY
  name: Publicly Available Content Database
  url: http://search.proquest.com/publiccontent
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2045-2322
EndPage 15
ExternalDocumentID oai_doaj_org_article_9b0eedb8063c45d7aa50b8761ac3582f
PMC10774293
38191799
10_1038_s41598_024_51217_1
Genre Journal Article
GrantInformation_xml – fundername: Canadian Institutes of Health Research
  grantid: CGS-D
  funderid: http://dx.doi.org/10.13039/501100000024
– fundername: Cancer Research Society
  grantid: 878350
  funderid: http://dx.doi.org/10.13039/100009326
– fundername: CIHR
  grantid: CGS-D
GroupedDBID 0R~
3V.
4.4
53G
5VS
7X7
88A
88E
88I
8FE
8FH
8FI
8FJ
AAFWJ
AAJSJ
AAKDD
ABDBF
ABUWG
ACGFS
ACSMW
ACUHS
ADBBV
ADRAZ
AENEX
AEUYN
AFKRA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
DWQXO
EBD
EBLON
EBS
ESX
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HH5
HMCUK
HYE
KQ8
LK8
M0L
M1P
M2P
M48
M7P
M~E
NAO
OK1
PIMPY
PQQKQ
PROAC
PSQYO
RNT
RNTTT
RPM
SNYQT
UKHRP
AASML
AAYXX
AFFHD
AFPKN
CITATION
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
K9.
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
PUEGO
5PM
ID FETCH-LOGICAL-c541t-e36c88ad3792e1645dfe1ebeb100784b89a3a61ea147b5a83cd4011fbd5a36a33
IEDL.DBID DOA
ISICitedReferencesCount 10
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001138677500059&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 2045-2322
IngestDate Tue Oct 14 18:55:57 EDT 2025
Tue Nov 04 02:06:18 EST 2025
Thu Sep 04 20:06:25 EDT 2025
Tue Oct 07 07:47:44 EDT 2025
Wed Feb 19 02:08:50 EST 2025
Sat Nov 29 01:56:50 EST 2025
Tue Nov 18 21:53:57 EST 2025
Fri Feb 21 02:38:04 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-e36c88ad3792e1645dfe1ebeb100784b89a3a61ea147b5a83cd4011fbd5a36a33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
OpenAccessLink https://doaj.org/article/9b0eedb8063c45d7aa50b8761ac3582f
PMID 38191799
PQID 2911668322
PQPubID 2041939
PageCount 15
ParticipantIDs doaj_primary_oai_doaj_org_article_9b0eedb8063c45d7aa50b8761ac3582f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10774293
proquest_miscellaneous_2912525250
proquest_journals_2911668322
pubmed_primary_38191799
crossref_citationtrail_10_1038_s41598_024_51217_1
crossref_primary_10_1038_s41598_024_51217_1
springer_journals_10_1038_s41598_024_51217_1
PublicationCentury 2000
PublicationDate 2024-01-08
PublicationDateYYYYMMDD 2024-01-08
PublicationDate_xml – month: 01
  year: 2024
  text: 2024-01-08
  day: 08
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Scientific reports
PublicationTitleAbbrev Sci Rep
PublicationTitleAlternate Sci Rep
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Fauriat, Long, Ljunggren, Bryceson (CR47) 2010; 115
Jerby-Arnon (CR38) 2018; 175
Yang (CR25) 2019; 38
Latha (CR30) 2018
Lambrechts (CR41) 2018; 24
Merchand-Reyes (CR66) 2019; 203
Fu (CR16) 2020; 6
Lee (CR43) 2020; 52
Qian (CR39) 2020; 30
Anderson, Joller, Kuchroo (CR69) 2016; 44
Liu (CR11) 2003; 270
Morris (CR29) 2020; 52
Bartczak (CR18) 2016; 16
Ostapchuk (CR61) 2022; 51
Rabizadeh (CR36) 2015; 136
Weigent, Stanton, Johnson (CR46) 1983; 41
Kiessling, Klein, Wigzell (CR81) 1975; 5
Marsden (CR1) 2003; 112
Levy (CR13) 2000; 156
Zheng, Yu, Wu, Wu (CR21) 2018; 66
Tang (CR33) 2017; 7
Zhou (CR9) 2019; 5
Su (CR35) 2008; 14
Yu (CR48) 2009; 10
Winkler, Abisoye-Ogunniyan, Metcalf, Werb (CR74) 2020; 11
Roby (CR77) 2000; 21
Yu (CR52) 2018; 13
Ai (CR20) 2018; 20
Foerster (CR14) 2010; 53
Yan (CR31) 2015; 107
Clement (CR65) 2014; 111
Shalev (CR5) 2008; 180
Melnyk (CR22) 2011; 40
Yan (CR28) 2019; 10
Pan (CR19) 2018
Cook, Vanderhyden (CR37) 2023; 8
Johnston, Schachne, Bystryn (CR71) 1987; 6
Liu (CR34) 2012; 32
Joller (CR27) 2014; 40
Wing, Ekmark, Karlsson, Rudin, Suri-Payer (CR49) 2002; 106
McCloskey, Rodriguez, Galpin, Vanderhyden (CR55) 2018; 10
Vivier, Tomasello, Baratin, Walzer, Ugolini (CR63) 2008; 9
Khattar (CR67) 2013; 8
Carlino, Larkin, Long (CR76) 2021; 398
Martin (CR73) 2016; 11
Rodriguez (CR54) 2022; 2
Rodriguez, Galpin, McCloskey, Vanderhyden (CR56) 2018; 10
Shalev (CR6) 2009; 49
Yu, Su, Huang, Wang (CR7) 2021; 12
Ribas (CR58) 2017; 170
Walton (CR78) 2016; 76
Bassez (CR42) 2021; 27
de Rham (CR64) 2007; 9
Wang (CR17) 2015; 9
Ding (CR10) 1998; 440
Cook, Vanderhyden (CR83) 2022; 8
Elliot (CR50) 2021; 54
Lechner (CR70) 2013; 36
Stojdl (CR59) 2003; 4
Tumilasci (CR82) 2008; 82
Zhu (CR12) 2017; 13
Van Tong (CR15) 2018; 18
Alter, Malenfant, Altfeld (CR62) 2004; 294
Geistlinger (CR40) 2020; 80
Wensveen, Jelenčić, Polić (CR45) 2018; 9
Achard (CR60) 2018; 31
McCloskey (CR79) 2014; 4
Liu (CR3) 2008; 38
Zhu (CR24) 2018; 9
Yang (CR8) 2013; 62
Marazzi (CR4) 1998; 161
Bartczak (CR23) 2017; 23
Ning (CR2) 2005; 174
Hamanishi, Mandai, Konishi (CR75) 2016; 28
Matheoud (CR72) 2011; 6
Bonaventura (CR53) 2019; 10
Luft (CR51) 2018; 154
Chiocca, Rabkin (CR57) 2014; 2
Overwijk, Restifo (CR80) 2001; 20
Martinet (CR44) 2015; 11
Qin (CR32) 2014; 31
Chan (CR26) 2003; 170
Fontenot (CR68) 2005; 22
J Wang (51217_CR17) 2015; 9
K Wing (51217_CR49) 2002; 106
G Alter (51217_CR62) 2004; 294
PA Marsden (51217_CR1) 2003; 112
H Liu (51217_CR3) 2008; 38
DF Stojdl (51217_CR59) 2003; 4
O Luft (51217_CR51) 2018; 154
E Vivier (51217_CR63) 2008; 9
Y Liu (51217_CR34) 2012; 32
M Tang (51217_CR33) 2017; 7
J Walton (51217_CR78) 2016; 76
J Qian (51217_CR39) 2020; 30
FM Wensveen (51217_CR45) 2018; 9
KF Roby (51217_CR77) 2000; 21
R Khattar (51217_CR67) 2013; 8
MC Melnyk (51217_CR22) 2011; 40
W-Z Qin (51217_CR32) 2014; 31
J Hamanishi (51217_CR75) 2016; 28
G Pan (51217_CR19) 2018
H Van Tong (51217_CR15) 2018; 18
L Geistlinger (51217_CR40) 2020; 80
Y Zhou (51217_CR9) 2019; 5
YO Ostapchuk (51217_CR61) 2022; 51
M Yu (51217_CR7) 2021; 12
VF Tumilasci (51217_CR82) 2008; 82
N Joller (51217_CR27) 2014; 40
D Matheoud (51217_CR72) 2011; 6
M Clement (51217_CR65) 2014; 111
Y Fu (51217_CR16) 2020; 6
G Ai (51217_CR20) 2018; 20
P Bonaventura (51217_CR53) 2019; 10
S Marazzi (51217_CR4) 1998; 161
C de Rham (51217_CR64) 2007; 9
JW Ding (51217_CR10) 1998; 440
H-O Lee (51217_CR43) 2020; 52
CWY Chan (51217_CR26) 2003; 170
DP Cook (51217_CR83) 2022; 8
M Liu (51217_CR11) 2003; 270
K Foerster (51217_CR14) 2010; 53
Y Zhu (51217_CR24) 2018; 9
L Jerby-Arnon (51217_CR38) 2018; 175
E Rabizadeh (51217_CR36) 2015; 136
L Martinet (51217_CR44) 2015; 11
D Johnston (51217_CR71) 1987; 6
C Yang (51217_CR8) 2013; 62
M Yang (51217_CR25) 2019; 38
Q Ning (51217_CR2) 2005; 174
K Su (51217_CR35) 2008; 14
JW Yu (51217_CR52) 2018; 13
CW McCloskey (51217_CR79) 2014; 4
I Shalev (51217_CR5) 2008; 180
J Winkler (51217_CR74) 2020; 11
A Bartczak (51217_CR23) 2017; 23
WW Overwijk (51217_CR80) 2001; 20
D Lambrechts (51217_CR41) 2018; 24
Z Zheng (51217_CR21) 2018; 66
DA Weigent (51217_CR46) 1983; 41
X Yu (51217_CR48) 2009; 10
TAE Elliot (51217_CR50) 2021; 54
MG Lechner (51217_CR70) 2013; 36
R Kiessling (51217_CR81) 1975; 5
AC Anderson (51217_CR69) 2016; 44
AB Morris (51217_CR29) 2020; 52
C Fauriat (51217_CR47) 2010; 115
JD Fontenot (51217_CR68) 2005; 22
I Shalev (51217_CR6) 2009; 49
GM Rodriguez (51217_CR56) 2018; 10
K Latha (51217_CR30) 2018
MS Carlino (51217_CR76) 2021; 398
J Yan (51217_CR28) 2019; 10
A Bartczak (51217_CR18) 2016; 16
E Chiocca (51217_CR57) 2014; 2
GM Rodriguez (51217_CR54) 2022; 2
CW McCloskey (51217_CR55) 2018; 10
A Ribas (51217_CR58) 2017; 170
SD Martin (51217_CR73) 2016; 11
Y Zhu (51217_CR12) 2017; 13
A Bassez (51217_CR42) 2021; 27
C Achard (51217_CR60) 2018; 31
GA Levy (51217_CR13) 2000; 156
G Merchand-Reyes (51217_CR66) 2019; 203
DP Cook (51217_CR37) 2023; 8
J Yan (51217_CR31) 2015; 107
References_xml – volume: 2
  start-page: 417
  year: 2022
  end-page: 433
  ident: CR54
  article-title: The tumor immune profile of murine ovarian cancer models: An essential tool for ovarian cancer immunotherapy research
  publication-title: Cancer Res. Commun.
  doi: 10.1158/2767-9764.CRC-22-0017
– volume: 49
  start-page: 387
  year: 2009
  end-page: 397
  ident: CR6
  article-title: The novel CD4+ CD25+ regulatory T cell effector molecule fibrinogen-like protein 2 contributes to the outcome of murine fulminant viral hepatitis
  publication-title: Hepatology
  doi: 10.1002/hep.22684
– volume: 16
  start-page: 1739
  year: 2016
  end-page: 1750
  ident: CR18
  article-title: Overexpression of fibrinogen-like protein 2 promotes tolerance in a fully mismatched murine model of heart transplantation
  publication-title: Am. J. Transplant.
  doi: 10.1111/ajt.13696
– volume: 107
  start-page: 137
  year: 2015
  ident: CR31
  article-title: FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djv137
– volume: 13
  year: 2018
  ident: CR52
  article-title: Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0206223
– volume: 11
  start-page: 85
  year: 2015
  end-page: 97
  ident: CR44
  article-title: DNAM-1 expression marks an alternative program of NK cell maturation
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2015.03.006
– volume: 115
  start-page: 2167
  year: 2010
  end-page: 2176
  ident: CR47
  article-title: Regulation of human NK-cell cytokine and chemokine production by target cell recognition
  publication-title: Blood
  doi: 10.1182/blood-2009-08-238469
– volume: 22
  start-page: 329
  year: 2005
  end-page: 341
  ident: CR68
  article-title: Regulatory T cell lineage specification by the forkhead transcription factor foxp3
  publication-title: Immunity
  doi: 10.1016/j.immuni.2005.01.016
– volume: 4
  start-page: 53
  year: 2014
  ident: CR79
  article-title: A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2014.00053
– volume: 13
  start-page: 804
  year: 2017
  end-page: 814
  ident: CR12
  article-title: Stroma-derived Fibrinogen-like Protein 2 activates cancer-associated fibroblasts to promote tumor growth in lung cancer
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.19398
– year: 2018
  ident: CR19
  article-title: Soluble fibrinogen-like protein 2 ameliorates acute rejection of liver transplantation in rat via inducing Kupffer cells M2 polarization
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1528
– volume: 175
  start-page: 984
  year: 2018
  end-page: 997.e24
  ident: CR38
  article-title: A cancer cell program promotes T cell exclusion and resistance to checkpoint blockade
  publication-title: Cell
  doi: 10.1016/j.cell.2018.09.006
– volume: 40
  start-page: 569
  year: 2014
  end-page: 581
  ident: CR27
  article-title: Treg cells expressing the co-inhibitory molecule TIGIT selectively inhibit pro-inflammatory Th1 and Th17 cell responses
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.02.012
– volume: 2
  start-page: 295
  year: 2014
  end-page: 300
  ident: CR57
  article-title: Oncolytic viruses and their application to cancer immunotherapy
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0015
– volume: 106
  start-page: 190
  year: 2002
  end-page: 199
  ident: CR49
  article-title: Characterization of human CD25+ CD4+ T cells in thymus, cord and adult blood
  publication-title: Immunology
  doi: 10.1046/j.1365-2567.2002.01412.x
– volume: 111
  start-page: E1101
  year: 2014
  end-page: E1110
  ident: CR65
  article-title: CD31 is a key coinhibitory receptor in the development of immunogenic dendritic cells
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1314505111
– volume: 20
  start-page: 20.1
  year: 2001
  ident: CR80
  article-title: B16 as a mouse model for human melanoma
  publication-title: Curr. Protoc. Immunol.
– volume: 203
  start-page: 3216
  year: 2019
  end-page: 3224
  ident: CR66
  article-title: CD31 acts as a checkpoint molecule and is modulated by FcγR-mediated signaling in monocytes
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1900059
– volume: 31
  start-page: 181
  year: 2014
  ident: CR32
  article-title: Overexpression of fibrinogen-like protein 2 induces epithelial-to-mesenchymal transition and promotes tumor progression in colorectal carcinoma
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-014-0181-7
– volume: 8
  start-page: eabi7640
  year: 2023
  ident: CR37
  article-title: Transcriptional census of epithelial-mesenchymal plasticity in cancer
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abi7640
– volume: 6
  start-page: 9269
  year: 2020
  ident: CR16
  article-title: Blood-stage malaria parasites manipulate host innate immune responses through the induction of sFGL2
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aay9269
– volume: 32
  start-page: 1585
  year: 2012
  end-page: 1595
  ident: CR34
  article-title: Downregulation of FGL2/prothrombinase delays HCCLM6 xenograft tumour growth and decreases tumour angiogenesis
  publication-title: Liver Int.
  doi: 10.1111/j.1478-3231.2012.02865.x
– volume: 8
  year: 2013
  ident: CR67
  article-title: Targeted deletion of FGL2 leads to increased early viral replication and enhanced adaptive immunity in a murine model of acute viral hepatitis caused by LCMV WE
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0072309
– volume: 156
  start-page: 1217
  year: 2000
  end-page: 1225
  ident: CR13
  article-title: Molecular and functional analysis of the human prothrombinase gene (HFGL2) and its role in viral hepatitis
  publication-title: Am. J. Pathol.
  doi: 10.1016/S0002-9440(10)64992-9
– volume: 18
  start-page: 553
  year: 2018
  ident: CR15
  article-title: Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases
  publication-title: BMC Infect. Dis.
  doi: 10.1186/s12879-018-3473-2
– volume: 66
  start-page: 52
  year: 2018
  end-page: 58
  ident: CR21
  article-title: FGL2 knockdown improves heart function through regulation of TLR9 signaling in the experimental autoimmune myocarditis rats
  publication-title: Immunol. Res.
  doi: 10.1007/s12026-017-8965-4
– volume: 21
  start-page: 585
  year: 2000
  end-page: 591
  ident: CR77
  article-title: Development of a syngeneic mouse model for events related to ovarian cancer
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/21.4.585
– volume: 6
  year: 2011
  ident: CR72
  article-title: Dendritic cells crosspresent antigens from live B16 Cells more efficiently than from apoptotic cells and protect from melanoma in a therapeutic model
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0019104
– volume: 38
  start-page: 3114
  year: 2008
  end-page: 3126
  ident: CR3
  article-title: The FGL2-FcgammaRIIB pathway: A novel mechanism leading to immunosuppression
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200838338
– volume: 51
  start-page: 138
  year: 2022
  end-page: 153
  ident: CR61
  article-title: Fc receptor is involved in Nk cell functional anergy induced by Miapaca2 tumor cell line
  publication-title: Immunol. Invest.
  doi: 10.1080/08820139.2020.1813757
– volume: 180
  start-page: 249
  year: 2008
  end-page: 260
  ident: CR5
  article-title: Targeted deletion of fgl2 leads to impaired regulatory T cell activity and development of autoimmune glomerulonephritis
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.180.1.249
– volume: 31
  start-page: 17
  year: 2018
  end-page: 24
  ident: CR60
  article-title: Lighting a fire in the tumor microenvironment using oncolytic immunotherapy
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2018.04.020
– volume: 62
  start-page: 1204
  year: 2013
  end-page: 1213
  ident: CR8
  article-title: Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-302239
– volume: 4
  start-page: 263
  year: 2003
  end-page: 275
  ident: CR59
  article-title: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(03)00241-1
– volume: 82
  start-page: 8487
  year: 2008
  end-page: 8499
  ident: CR82
  article-title: Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to Vesicular Stomatitis Virus-induced oncolysis
  publication-title: J. Virol.
  doi: 10.1128/JVI.00851-08
– volume: 9
  start-page: 441
  year: 2018
  ident: CR45
  article-title: NKG2D: A master regulator of immune cell responsiveness
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00441
– volume: 80
  start-page: 4335
  year: 2020
  end-page: 4345
  ident: CR40
  article-title: Multiomic analysis of subtype evolution and heterogeneity in high-grade serous ovarian carcinoma
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-0521
– volume: 10
  start-page: 244
  year: 2018
  ident: CR55
  article-title: Ovarian cancer immunotherapy: Preclinical models and emerging therapeutics
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10080244
– volume: 10
  start-page: 168
  year: 2019
  ident: CR53
  article-title: Cold tumors: A therapeutic challenge for immunotherapy
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00168
– volume: 12
  start-page: 133
  year: 2021
  ident: CR7
  article-title: Single-cell sequencing reveals the novel role of Ezh2 in NK cell maturation and function
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.724276
– volume: 10
  start-page: 48
  year: 2009
  end-page: 57
  ident: CR48
  article-title: The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.1674
– volume: 52
  start-page: 136
  year: 2020
  end-page: 150.e6
  ident: CR29
  article-title: Signaling through the inhibitory Fc receptor FcγRIIB induces CD8+ T cell apoptosis to limit T cell immunity
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.12.006
– volume: 6
  start-page: 108
  year: 1987
  end-page: 120
  ident: CR71
  article-title: Identification of immunogenic B16 melanoma-associated antigens
  publication-title: J. Biol. Response Mod.
– volume: 136
  start-page: 118
  year: 2015
  end-page: 124
  ident: CR36
  article-title: The cell-membrane prothrombinase, fibrinogen-like protein 2, promotes angiogenesis and tumor development
  publication-title: Thromb. Res.
  doi: 10.1016/j.thromres.2014.11.023
– volume: 170
  start-page: 4036
  year: 2003
  end-page: 4044
  ident: CR26
  article-title: Soluble fibrinogen-like protein 2/fibroleukin exhibits immunosuppressive properties: Suppressing T cell proliferation and inhibiting maturation of bone marrow-derived dendritic cells
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.170.8.4036
– volume: 170
  start-page: 1109
  year: 2017
  end-page: 1119.e10
  ident: CR58
  article-title: Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.027
– volume: 8
  start-page: eabi7640
  year: 2022
  ident: CR83
  article-title: Transcriptional census of epithelial-mesenchymal plasticity in cancer
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abi7640
– volume: 9
  start-page: 87
  year: 2018
  ident: CR24
  article-title: Control of intestinal inflammation, colitis-associated tumorigenesis, and macrophage polarization by fibrinogen-like protein 2
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00087
– volume: 44
  start-page: 989
  year: 2016
  end-page: 1004
  ident: CR69
  article-title: Lag-3, Tim-3, and TIGIT co-inhibitory receptors with specialized functions in immune regulation
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.001
– volume: 54
  start-page: 2481
  year: 2021
  end-page: 2496.e6
  ident: CR50
  article-title: Antigen and checkpoint receptor engagement recalibrates T cell receptor signal strength
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.08.020
– volume: 10
  start-page: 242
  year: 2018
  ident: CR56
  article-title: The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10080242
– volume: 11
  start-page: 5120
  year: 2020
  ident: CR74
  article-title: Concepts of extracellular matrix remodelling in tumour progression and metastasis
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18794-x
– volume: 174
  start-page: 7403
  year: 2005
  end-page: 7411
  ident: CR2
  article-title: Role of fibrinogen-like protein 2 prothrombinase/fibroleukin in experimental and human allograft rejection
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.174.11.7403
– volume: 7
  start-page: 12676
  year: 2017
  ident: CR33
  article-title: Increased expression of Fibrinogen-Like Protein 2 is associated with poor prognosis in patients with clear cell renal cell carcinoma
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-13149-x
– volume: 40
  start-page: 269
  year: 2011
  end-page: 278
  ident: CR22
  article-title: The prothrombinase activity of FGL2 contributes to the pathogenesis of experimental arthritis
  publication-title: Scand. J. Rheumatol.
  doi: 10.3109/03009742.2010.536163
– year: 2018
  ident: CR30
  article-title: The role of Fibrinogen-Like Protein 2 on immunosuppression and malignant progression in glioma
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djy107
– volume: 9
  start-page: R125
  year: 2007
  ident: CR64
  article-title: The proinflammatory cytokines IL-2, IL-15 and IL-21 modulate the repertoire of mature human natural killer cell receptors
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar2336
– volume: 5
  start-page: 112
  year: 1975
  end-page: 117
  ident: CR81
  article-title: ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.1830050208
– volume: 270
  start-page: 2274
  year: 2003
  end-page: 2286
  ident: CR11
  article-title: Gene transcription of fgl2 in endothelial cells is controlled by Ets-1 and Oct-1 and requires the presence of both Sp1 and Sp3
  publication-title: Eur. J. Biochem.
  doi: 10.1046/j.1432-1033.2003.03595.x
– volume: 10
  start-page: 448
  year: 2019
  ident: CR28
  article-title: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-08271-x
– volume: 9
  year: 2015
  ident: CR17
  article-title: Deletion of fibrinogen-like protein 2 (FGL-2), a novel CD4+ CD25+ Treg effector molecule, leads to improved control of Echinococcus multilocularis infection in mice
  publication-title: PLoS Negl. Trop. Dis.
  doi: 10.1371/journal.pntd.0003755
– volume: 52
  start-page: 594
  year: 2020
  end-page: 603
  ident: CR43
  article-title: Lineage-dependent gene expression programs influence the immune landscape of colorectal cancer
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-020-0636-z
– volume: 23
  start-page: 2673
  year: 2017
  end-page: 2684
  ident: CR23
  article-title: Overexpression of fibrinogen-like protein 2 protects against T cell-induced colitis
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v23.i15.2673
– volume: 24
  start-page: 1277
  year: 2018
  end-page: 1289
  ident: CR41
  article-title: Phenotype molding of stromal cells in the lung tumor microenvironment
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0096-5
– volume: 9
  start-page: 503
  year: 2008
  end-page: 510
  ident: CR63
  article-title: Functions of natural killer cells
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1582
– volume: 440
  start-page: 609
  year: 1998
  end-page: 618
  ident: CR10
  article-title: Expression of the fgl2 and its protein product (prothrombinase) in tissues during murine hepatitis virus strain-3 (MHV-3) infection
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-1-4615-5331-1_79
– volume: 161
  start-page: 138
  year: 1998
  end-page: 147
  ident: CR4
  article-title: Characterization of human fibroleukin, a fibrinogen-like protein secreted by T lymphocytes
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.161.1.138
– volume: 27
  start-page: 820
  year: 2021
  end-page: 832
  ident: CR42
  article-title: A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01323-8
– volume: 154
  start-page: 476
  year: 2018
  end-page: 489
  ident: CR51
  article-title: Inhibition of the Fibrinogen-Like Protein 2: Fcγ RIIB/RIII immunosuppressive pathway enhances antiviral T-cell and B-cell responses leading to clearance of lymphocytic choriomeningitis virus clone 13
  publication-title: Immunology
  doi: 10.1111/imm.12897
– volume: 14
  start-page: 5980
  year: 2008
  end-page: 5989
  ident: CR35
  article-title: Fibrinogen-like protein 2/fibroleukin prothrombinase contributes to tumor hypercoagulability via IL-2 and IFN-gamma
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.14.5980
– volume: 30
  start-page: 745
  year: 2020
  end-page: 762
  ident: CR39
  article-title: A pan-cancer blueprint of the heterogeneous tumor microenvironment revealed by single-cell profiling
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0355-0
– volume: 41
  start-page: 992
  year: 1983
  end-page: 997
  ident: CR46
  article-title: Interleukin 2 enhances natural killer cell activity through induction of gamma interferon
  publication-title: Infect. Immun.
  doi: 10.1128/iai.41.3.992-997.1983
– volume: 112
  start-page: 58
  year: 2003
  end-page: 66
  ident: CR1
  article-title: The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI18114
– volume: 5
  start-page: eaax0629
  year: 2019
  ident: CR9
  article-title: Fibrinogen-like protein 2 controls sepsis catabasis by interacting with resolvin Dp5
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aax0629
– volume: 20
  year: 2018
  ident: CR20
  article-title: Soluble Fgl2 restricts autoimmune hepatitis progression via suppressing Tc17 and conventional CD8+ T cell function
  publication-title: J. Gene Med.
  doi: 10.1002/jgm.3023
– volume: 36
  start-page: 477
  year: 2013
  end-page: 489
  ident: CR70
  article-title: Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy
  publication-title: J. Immunother.
  doi: 10.1097/01.cji.0000436722.46675.4a
– volume: 11
  year: 2016
  ident: CR73
  article-title: Low Mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0155189
– volume: 28
  start-page: 339
  year: 2016
  end-page: 348
  ident: CR75
  article-title: Immune checkpoint inhibition in ovarian cancer
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxw020
– volume: 53
  start-page: 608
  year: 2010
  end-page: 615
  ident: CR14
  article-title: The novel immunoregulatory molecule FGL2: A potential biomarker for severity of chronic hepatitis C virus infection
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2010.04.020
– volume: 38
  start-page: 351
  year: 2019
  ident: CR25
  article-title: Soluble fibrinogen-like protein 2 promotes the growth of hepatocellular carcinoma via attenuating dendritic cell-mediated cytotoxic T cell activity
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-019-1326-5
– volume: 294
  start-page: 15
  year: 2004
  end-page: 22
  ident: CR62
  article-title: CD107a as a functional marker for the identification of natural killer cell activity
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2004.08.008
– volume: 76
  start-page: 6118
  year: 2016
  end-page: 6129
  ident: CR78
  article-title: CRISPR/Cas9-mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian high-grade serous carcinoma
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-1272
– volume: 398
  start-page: 1002
  year: 2021
  end-page: 1014
  ident: CR76
  article-title: Immune checkpoint inhibitors in melanoma
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01206-X
– volume: 80
  start-page: 4335
  year: 2020
  ident: 51217_CR40
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-20-0521
– volume: 175
  start-page: 984
  year: 2018
  ident: 51217_CR38
  publication-title: Cell
  doi: 10.1016/j.cell.2018.09.006
– volume: 154
  start-page: 476
  year: 2018
  ident: 51217_CR51
  publication-title: Immunology
  doi: 10.1111/imm.12897
– volume: 36
  start-page: 477
  year: 2013
  ident: 51217_CR70
  publication-title: J. Immunother.
  doi: 10.1097/01.cji.0000436722.46675.4a
– volume: 8
  start-page: eabi7640
  year: 2022
  ident: 51217_CR83
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abi7640
– volume: 31
  start-page: 17
  year: 2018
  ident: 51217_CR60
  publication-title: EBioMedicine
  doi: 10.1016/j.ebiom.2018.04.020
– volume: 38
  start-page: 3114
  year: 2008
  ident: 51217_CR3
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.200838338
– volume: 24
  start-page: 1277
  year: 2018
  ident: 51217_CR41
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0096-5
– volume: 21
  start-page: 585
  year: 2000
  ident: 51217_CR77
  publication-title: Carcinogenesis
  doi: 10.1093/carcin/21.4.585
– volume: 66
  start-page: 52
  year: 2018
  ident: 51217_CR21
  publication-title: Immunol. Res.
  doi: 10.1007/s12026-017-8965-4
– volume: 10
  start-page: 448
  year: 2019
  ident: 51217_CR28
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-08271-x
– volume: 27
  start-page: 820
  year: 2021
  ident: 51217_CR42
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01323-8
– volume: 170
  start-page: 1109
  year: 2017
  ident: 51217_CR58
  publication-title: Cell
  doi: 10.1016/j.cell.2017.08.027
– volume: 156
  start-page: 1217
  year: 2000
  ident: 51217_CR13
  publication-title: Am. J. Pathol.
  doi: 10.1016/S0002-9440(10)64992-9
– volume: 2
  start-page: 417
  year: 2022
  ident: 51217_CR54
  publication-title: Cancer Res. Commun.
  doi: 10.1158/2767-9764.CRC-22-0017
– volume: 8
  year: 2013
  ident: 51217_CR67
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0072309
– volume: 9
  year: 2015
  ident: 51217_CR17
  publication-title: PLoS Negl. Trop. Dis.
  doi: 10.1371/journal.pntd.0003755
– volume: 14
  start-page: 5980
  year: 2008
  ident: 51217_CR35
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.14.5980
– volume: 16
  start-page: 1739
  year: 2016
  ident: 51217_CR18
  publication-title: Am. J. Transplant.
  doi: 10.1111/ajt.13696
– volume: 174
  start-page: 7403
  year: 2005
  ident: 51217_CR2
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.174.11.7403
– year: 2018
  ident: 51217_CR19
  publication-title: Cancer Med.
  doi: 10.1002/cam4.1528
– volume: 9
  start-page: R125
  year: 2007
  ident: 51217_CR64
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/ar2336
– volume: 18
  start-page: 553
  year: 2018
  ident: 51217_CR15
  publication-title: BMC Infect. Dis.
  doi: 10.1186/s12879-018-3473-2
– volume: 11
  start-page: 85
  year: 2015
  ident: 51217_CR44
  publication-title: Cell Rep.
  doi: 10.1016/j.celrep.2015.03.006
– volume: 9
  start-page: 87
  year: 2018
  ident: 51217_CR24
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00087
– volume: 20
  start-page: 20.1
  year: 2001
  ident: 51217_CR80
  publication-title: Curr. Protoc. Immunol.
– volume: 82
  start-page: 8487
  year: 2008
  ident: 51217_CR82
  publication-title: J. Virol.
  doi: 10.1128/JVI.00851-08
– volume: 270
  start-page: 2274
  year: 2003
  ident: 51217_CR11
  publication-title: Eur. J. Biochem.
  doi: 10.1046/j.1432-1033.2003.03595.x
– volume: 28
  start-page: 339
  year: 2016
  ident: 51217_CR75
  publication-title: Int. Immunol.
  doi: 10.1093/intimm/dxw020
– volume: 398
  start-page: 1002
  year: 2021
  ident: 51217_CR76
  publication-title: Lancet
  doi: 10.1016/S0140-6736(21)01206-X
– volume: 112
  start-page: 58
  year: 2003
  ident: 51217_CR1
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI18114
– volume: 4
  start-page: 53
  year: 2014
  ident: 51217_CR79
  publication-title: Front. Oncol.
  doi: 10.3389/fonc.2014.00053
– volume: 30
  start-page: 745
  year: 2020
  ident: 51217_CR39
  publication-title: Cell Res.
  doi: 10.1038/s41422-020-0355-0
– volume: 107
  start-page: 137
  year: 2015
  ident: 51217_CR31
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djv137
– volume: 294
  start-page: 15
  year: 2004
  ident: 51217_CR62
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2004.08.008
– volume: 40
  start-page: 569
  year: 2014
  ident: 51217_CR27
  publication-title: Immunity
  doi: 10.1016/j.immuni.2014.02.012
– volume: 7
  start-page: 12676
  year: 2017
  ident: 51217_CR33
  publication-title: Sci. Rep.
  doi: 10.1038/s41598-017-13149-x
– volume: 115
  start-page: 2167
  year: 2010
  ident: 51217_CR47
  publication-title: Blood
  doi: 10.1182/blood-2009-08-238469
– volume: 440
  start-page: 609
  year: 1998
  ident: 51217_CR10
  publication-title: Adv. Exp. Med. Biol.
  doi: 10.1007/978-1-4615-5331-1_79
– volume: 62
  start-page: 1204
  year: 2013
  ident: 51217_CR8
  publication-title: Gut
  doi: 10.1136/gutjnl-2012-302239
– volume: 11
  year: 2016
  ident: 51217_CR73
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0155189
– volume: 76
  start-page: 6118
  year: 2016
  ident: 51217_CR78
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-16-1272
– volume: 203
  start-page: 3216
  year: 2019
  ident: 51217_CR66
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1900059
– volume: 22
  start-page: 329
  year: 2005
  ident: 51217_CR68
  publication-title: Immunity
  doi: 10.1016/j.immuni.2005.01.016
– volume: 31
  start-page: 181
  year: 2014
  ident: 51217_CR32
  publication-title: Med. Oncol.
  doi: 10.1007/s12032-014-0181-7
– volume: 20
  year: 2018
  ident: 51217_CR20
  publication-title: J. Gene Med.
  doi: 10.1002/jgm.3023
– volume: 12
  start-page: 133
  year: 2021
  ident: 51217_CR7
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.724276
– volume: 49
  start-page: 387
  year: 2009
  ident: 51217_CR6
  publication-title: Hepatology
  doi: 10.1002/hep.22684
– volume: 6
  start-page: 9269
  year: 2020
  ident: 51217_CR16
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aay9269
– volume: 5
  start-page: eaax0629
  year: 2019
  ident: 51217_CR9
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aax0629
– volume: 161
  start-page: 138
  year: 1998
  ident: 51217_CR4
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.161.1.138
– volume: 106
  start-page: 190
  year: 2002
  ident: 51217_CR49
  publication-title: Immunology
  doi: 10.1046/j.1365-2567.2002.01412.x
– volume: 51
  start-page: 138
  year: 2022
  ident: 51217_CR61
  publication-title: Immunol. Invest.
  doi: 10.1080/08820139.2020.1813757
– volume: 6
  year: 2011
  ident: 51217_CR72
  publication-title: PLOS ONE
  doi: 10.1371/journal.pone.0019104
– volume: 13
  year: 2018
  ident: 51217_CR52
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0206223
– volume: 136
  start-page: 118
  year: 2015
  ident: 51217_CR36
  publication-title: Thromb. Res.
  doi: 10.1016/j.thromres.2014.11.023
– volume: 32
  start-page: 1585
  year: 2012
  ident: 51217_CR34
  publication-title: Liver Int.
  doi: 10.1111/j.1478-3231.2012.02865.x
– volume: 41
  start-page: 992
  year: 1983
  ident: 51217_CR46
  publication-title: Infect. Immun.
  doi: 10.1128/iai.41.3.992-997.1983
– volume: 10
  start-page: 168
  year: 2019
  ident: 51217_CR53
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2019.00168
– volume: 52
  start-page: 136
  year: 2020
  ident: 51217_CR29
  publication-title: Immunity
  doi: 10.1016/j.immuni.2019.12.006
– volume: 54
  start-page: 2481
  year: 2021
  ident: 51217_CR50
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.08.020
– volume: 10
  start-page: 244
  year: 2018
  ident: 51217_CR55
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10080244
– volume: 9
  start-page: 503
  year: 2008
  ident: 51217_CR63
  publication-title: Nat. Immunol.
  doi: 10.1038/ni1582
– year: 2018
  ident: 51217_CR30
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djy107
– volume: 8
  start-page: eabi7640
  year: 2023
  ident: 51217_CR37
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.abi7640
– volume: 5
  start-page: 112
  year: 1975
  ident: 51217_CR81
  publication-title: Eur. J. Immunol.
  doi: 10.1002/eji.1830050208
– volume: 40
  start-page: 269
  year: 2011
  ident: 51217_CR22
  publication-title: Scand. J. Rheumatol.
  doi: 10.3109/03009742.2010.536163
– volume: 38
  start-page: 351
  year: 2019
  ident: 51217_CR25
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-019-1326-5
– volume: 13
  start-page: 804
  year: 2017
  ident: 51217_CR12
  publication-title: Int. J. Biol. Sci.
  doi: 10.7150/ijbs.19398
– volume: 53
  start-page: 608
  year: 2010
  ident: 51217_CR14
  publication-title: J. Hepatol.
  doi: 10.1016/j.jhep.2010.04.020
– volume: 23
  start-page: 2673
  year: 2017
  ident: 51217_CR23
  publication-title: World J. Gastroenterol.
  doi: 10.3748/wjg.v23.i15.2673
– volume: 170
  start-page: 4036
  year: 2003
  ident: 51217_CR26
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.170.8.4036
– volume: 6
  start-page: 108
  year: 1987
  ident: 51217_CR71
  publication-title: J. Biol. Response Mod.
– volume: 2
  start-page: 295
  year: 2014
  ident: 51217_CR57
  publication-title: Cancer Immunol. Res.
  doi: 10.1158/2326-6066.CIR-14-0015
– volume: 180
  start-page: 249
  year: 2008
  ident: 51217_CR5
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.180.1.249
– volume: 52
  start-page: 594
  year: 2020
  ident: 51217_CR43
  publication-title: Nat. Genet.
  doi: 10.1038/s41588-020-0636-z
– volume: 11
  start-page: 5120
  year: 2020
  ident: 51217_CR74
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-18794-x
– volume: 10
  start-page: 242
  year: 2018
  ident: 51217_CR56
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers10080242
– volume: 4
  start-page: 263
  year: 2003
  ident: 51217_CR59
  publication-title: Cancer Cell
  doi: 10.1016/S1535-6108(03)00241-1
– volume: 44
  start-page: 989
  year: 2016
  ident: 51217_CR69
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.001
– volume: 111
  start-page: E1101
  year: 2014
  ident: 51217_CR65
  publication-title: Proc. Natl. Acad. Sci. USA
  doi: 10.1073/pnas.1314505111
– volume: 9
  start-page: 441
  year: 2018
  ident: 51217_CR45
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2018.00441
– volume: 10
  start-page: 48
  year: 2009
  ident: 51217_CR48
  publication-title: Nat. Immunol.
  doi: 10.1038/ni.1674
SSID ssj0000529419
Score 2.4628286
Snippet The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and impede...
Abstract The tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T cells (Tregs), which contribute to tumour escape and...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 787
SubjectTerms 631/67/1059/2325
631/67/580
Animal models
Animals
Antigen-Presenting Cells
BRCA2 protein
Breast cancer
Carcinoma, Ovarian Epithelial
CD226 antigen
CD25 antigen
CD40 antigen
CD86 antigen
Cell activation
Dendritic cells
Down-regulation
Female
Fgl2 protein
Fibrinogen
Glioblastoma
Humanities and Social Sciences
Humans
Immunoregulation
Immunotherapy
Liver cancer
Lymphocytes
Lymphocytes T
Macrophages
Male
Melanoma
Metastases
Mice
Monocytes
multidisciplinary
Natural killer cells
Oncolysis
Ovarian cancer
Ovarian Neoplasms - therapy
Prostate cancer
Prostatic Neoplasms
Science
Science (multidisciplinary)
Tumor Microenvironment
Tumors
SummonAdditionalLinks – databaseName: Biological Science Database
  dbid: M7P
  link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELaggMSFd2mgICNxg6jrOA_nhACxcKiqHgD1Zjl-tCvtOttNdhH_nhnHm2p59EJWymHtRHbmG3vG8yLkNdYa4MBlae5KuBmjUwV6Q-psnuUVXGWI4_5-XJ2ciLOz-jQeuHXRrXK7JoaF2rQaz8iPMuDKskT8vVteplg1Cq2rsYTGTXILsyTw4Lp3Op6xoBUrZ3WMlYExHXWwX2FMWZansNPBAs129qOQtv9vsuafLpO_2U3DdjS9_78TeUDuRUGUvh-Q85DcsP4RuTOUpvz5mPyYfj7O6DI469mO9usFPEDPQWnvL6jyhmJeTr9GSZUCSGfzmH6Xto5irMQGWgydYfSJpWgdwG50YefKtwsV3tBuQE9XnmoE3oqGmjzdE_Jt-unrxy9pLNKQ6iJnfWp5qYVQhld1ZkH3KoyzDJDRoPuFyBtRK65KZhXLq6ZQgmsDKh1zjSkULxXn-2TPt94eEOoUJkPKMm24zhteq6pwunZApokpC1cnhG1JJXXMYI6FNOYyWNK5kAN5JZBXBvJKlpA34zPLIX_Htb0_IALGnph7O_zRrs5lZGVZNxMQLBoBwp2G6VZKFZMG4M6UxrBjl5DDLeFlXBA6eUX1hLwam4GVkQLK23Yd-mQF_iYJeTrAbRzJoFjX8A3EDhB3hrrb4mcXIV04KPgVSB08IW-3mL0a17-_xbPrp_Gc3M2QjfA0ShySvX61ti_Ibb3pZ93qZeDDXwjsOok
  priority: 102
  providerName: ProQuest
Title FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models
URI https://link.springer.com/article/10.1038/s41598-024-51217-1
https://www.ncbi.nlm.nih.gov/pubmed/38191799
https://www.proquest.com/docview/2911668322
https://www.proquest.com/docview/2912525250
https://pubmed.ncbi.nlm.nih.gov/PMC10774293
https://doaj.org/article/9b0eedb8063c45d7aa50b8761ac3582f
Volume 14
WOSCitedRecordID wos001138677500059&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: DOA
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M~E
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVPQU
  databaseName: Biological Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M7P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/biologicalscijournals
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Health & Medical Collection
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: 7X7
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/healthcomplete
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: BENPR
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Publicly Available Content Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: PIMPY
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: http://search.proquest.com/publiccontent
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: Science Database
  customDbUrl:
  eissn: 2045-2322
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0000529419
  issn: 2045-2322
  databaseCode: M2P
  dateStart: 20110101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/sciencejournals
  providerName: ProQuest
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgA4kXxDeBURmJN4hW20nsPDK0AtJWRQhQebIc29kqdcnUpEX899w5aVn5fKGR_BC70ek-fHeJ73eEvMBeAwKsLE6qDAbnbGwgb4grn_BEwi8LddyfT-R0qmazvLjS6gvPhPXwwD3jDvNyDNt4qcCV2iR10ph0XMLDmbFY5Fnh7gtRz5Vkqkf15nnC8qFKBqg5bMFTYTUZT2LwcbA1sx1PFAD7fxdl_npY8qcvpsERTe6Q20MESV_3lN8l13x9j9zse0p-u0--Tt6ecHoZTtn5lnYryO2X9Ayy7e6cmtpRBNSsVxhiUtCu-WLAzaVNRbHIYQ0zjs6xbMRTfK2Py-iFX5i6uTDhCc0aEmxTU4sas6ShmU77gHyaHH988y4euivENk1YF3uRWaWMEzLnHpKm1FWegUhLPDehklLlRpiMecMSWaZGCesgF2NV6VIjMiPEQ7JXN7V_TGhlEMWIc-tARqXIjUwrm1fA5bHL0iqPCNtwWtsBehw7YCx0-AQulO6lo0E6OkhHs4i83P7nsgfe-OvqIxTgdiWCZocboEp6UCX9L1WKyMFG_Hqw5FZz8AZZhvteRJ5vp8EGUQKm9s0qrOEpXuOIPOq1ZUtJnxHnwAO1o0c7pO7O1PPzgPMNmbmEcEFE5NVG5X7Q9WdePPkfvHhKbnG0FXzZpA7IXrdc-Wfkhl1383Y5ItflTIZRjcj-0fG0-DAKBgjjKS9wlDDuF-9Piy_fARtsM-Y
linkProvider Directory of Open Access Journals
linkToHtml http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jb9QwFLaqFgSXskOggJHgBFFjZ3MOCLENrTqMeiioN9exnXakmWSYzKL-KX4j7znJVMPSWw9kpBzGTmQ731v8_BZCXmKtgRCozI-KBG7GaF_BvsEvbMSjFK7ExXF_76eDgTg-zg43yM8uFgbdKjue6Bi1qTTayHc5UGWSIP7eTX74WDUKT1e7EhoNLA7s-RK2bPXb_U_wfV9x3vt89HHPb6sK-DqO2My3YaKFUCZMM25hsxCbwjKYSo7-AiLKRaZClTCrWJTmsRKhNrAHYUVuYhUmCg2gwPK3QI3gwrkKHq5sOnhqFrGsjc2BNditQT5iDBuPfJCsIBDYmvxzZQL-ptv-6aL52zmtE3-9W__bwt0m262iTd83lHGHbNjyLrnelN48v0eWvS99TifOGdHWdDYfwwP0dFotZ2dUlYZi3tFyjpo4BSIcjtr0wrQqKMaCLKDF0CFG11iKpx_YjY7tSJXVWLk3VAsF1F1SjYQ1pa7mUH2ffLuSWT8gm2VV2keEFgqTPXGuTaijPMxUGhc6KwAWgUniIvMI66AhdZuhHQuFjKTzFAiFbOAkAU7SwUkyj7xePTNp8pNc2vsDIm7VE3OLuz-q6alsWZXM8gAUp1yA8qphuqlScZADOTOlMay68MhOBzTZMrxaXqDMIy9WzcCq8Auo0lZz14fH-As88rCB92okjeEggzUQa8BfG-p6Szk8c-nQWQBbGNBaPfKmo5GLcf17LR5fPo3n5Mbe0de-7O8PDp6QmxxJGC1vYodszqZz-5Rc04vZsJ4-czyAkpOrpp1fox6YCg
linkToPdf http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Jj9MwFLZGwyIu7EtgACPBCaLGzn5ACBgKo6mqHgDNzeN4manUJqXpovlr_Drec5KOyjK3OZBKOdROZDvf9_xsv4WQl5hrIASW-ZFN4Ka18iWsG3xrIh6lcCXOj_v7IB0Os6OjfLRDfna-MGhW2clEJ6h1pXCPvMeBlUmC-OvZ1ixitN9_N_vhYwYpPGnt0mk0EDk0Z2tYvtVvD_bhW7_ivP_p68cvfpthwFdxxBa-CROVZVKHac4NLBxibQ2DbhVoO5BFRZbLUCbMSBalRSyzUGlYjzBb6FiGicTNUBD_V1IMWu7MBkeb_R08QYtY3vrpwHj0apgr0Z-NRz7MsjA5sK250KUM-Jue-6e55m9ntm4q7N_6nwfxNrnZKuD0fcOYO2THlHfJtSYl59k9su5_HnA6c0aKpqaL5RQeoCfzar04pbLUFOORlkvU0CmQczxpww7TylL0EVlBiaZj9LoxFE9FsBqdmoksq6l0b6hWElhfUoWEm1OXi6i-T75dSq8fkN2yKs0jQq3EIFCcKx2qqAhzmcZW5RYgEugktrlHWAcTodrI7ZhAZCKcBUGYiQZaAqAlHLQE88jrzTOzJm7JhbU_IPo2NTHmuPujmp-IVoSJvAhAoSoyUGoVdDeVMg4KoDmTCt2trUf2OtCJVhDW4hxxHnmxKQYRhl9AlqZaujo8xl_gkYcN1DctaTYUchiDbIsEW03dLinHpy5MOgtgaQParEfedHw5b9e_x-Lxxd14Tq4DZcTgYHj4hNzgyGbckMv2yO5ivjRPyVW1Wozr-TMnDig5vmzq_AKpIqDH
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=FGL2+promotes+tumour+growth+and+attenuates+infiltration+of+activated+immune+cells+in+melanoma+and+ovarian+cancer+models&rft.jtitle=Scientific+reports&rft.au=Galpin%2C+Kristianne+J.+C.&rft.au=Rodriguez%2C+Galaxia+M.&rft.au=Maranda%2C+Vincent&rft.au=Cook%2C+David+P.&rft.date=2024-01-08&rft.issn=2045-2322&rft.eissn=2045-2322&rft.volume=14&rft.issue=1&rft_id=info:doi/10.1038%2Fs41598-024-51217-1&rft.externalDBID=n%2Fa&rft.externalDocID=10_1038_s41598_024_51217_1
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2045-2322&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2045-2322&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2045-2322&client=summon